Slide 1: FY24 Results Presentation
FY24 Results Presentation 29 August 2024
Slide 2: Smarter, Modular, Cloud Native
SMARTER Alcidion Group Limited (ASX: ALC) was founded with one simple belief: MODULAR Smart technology can drive meaningful change CLOUD NATIVE Alcidion is delivering smarter solutions for clinicians and enabling our clients to harness the power of their data. Alcidion’s platform, Miya Precision, de
Slide 3: About Alcidion
About Alcidion Alcidion is a healthcare software and informatics company providing an innovative technology platform to improve the efficiency and quality of patient care Our flagship platform, Miya Precision, is a modular platform flexible to customer priorities & budgets 40 Clients Miya Precision
Slide 4: Miya Precision… smarter solutions for clinicians
Device Agnostic Mobile enabled delivery supporting the next generation of clinicians and digital workflow Intuitive Interfaces and Dashboards Easy to receive, read and action whilst on the move, Miya digitising the task list Precision… Clinical Decision Support smarter Supporting clinical workflow a
Slide 5: Smarter Solutions for Clinicians
Smarter Solutions for Clinicians Powering Smarter Care Patient Virtual Operations Centre Specialised At the core of Alcidion’s solutions is our FHIR- based interoperability platform for smarter Flow Care Care decision support Industry leading digital Virtual care and remote Integrated Operations Eme
Slide 6: A sample of our customers
A sample of our customers . . . Alfred Health Western Health NT Health Journey Boards & IOC Collaboration Patient Flow, Command Capability Patient Flow & Command Capability South Tees NHS Trust Australian Defence Force Dartford & Gravesham NHS Miya EPR Longitudinal Health Record Miya EPR 6
Slide 7: FY24 Highlights
FY24 Highlights
Slide 8: FY24 – Executive Summary
FY24 – Executive Summary $37.1M ($7.1M) Operating 1 Revenue 8% Cashflow (FY24) 86.1% $4.3M Operating Gross Margin 7 bps Cashflow (H2 FY24) ($3.4M) $35.3M Underlying New FY24 EBITDA2 (FY24) $2.2M TCV3,4 Sales ($0.6M) $11.8M Underlying EBITDA Cash (H2 FY24) 1. Comparisons are to prior corresponding pe
Slide 9: FY24 – Executive Summary (cont.)
FY24 – Executive Summary (cont.) • North Cumbria NHS Trust1 (UK): Preferred supplier for new EPR2 solution; TCV expected in range of A$30-40M over 10 years New / • Hume Rural Health Alliance (AUS): Partnership using Miya Precision as an enterprise digital platform; $4M TCV over 5 years Expanded • So
Slide 10: FY24 Financials
FY24 Financials
Slide 11: Profit & Loss
Profit & Loss Annually recurring product revenue increasing, underpinning confidence in future profitability despite a decrease in total revenue Profit & loss (A$000) FY23 FY24 % change 1 • Product revenue of $26.2M (proxy for ARR), up 6% on pcp, includes: Recurring Product - M&S + Annual licences 1
Slide 12: Profit & Loss (H1 vs H2 FY24)
Profit & Loss (H1 vs H2 FY24) Significant impact of cost saving initiatives implemented in H2; Alcidion on clear path to profitability Profit & loss (A$000) H1'24 H2'24 % change 1• 19% reduction in staff costs in H2 vs H1 Total revenue 19,059 17,998 (6%) Direct costs (2,322) (2,815) 21% – Due to tim
Slide 13: Revenue Dashboard
Revenue Dashboard H1 H2 40.4 37.1 34.4 21.4 18.0 21.5 H1 vs H2 25.9 Geographical $37.1M Revenue Split 18.6 14.8 49% 51% Split (%) Total ($M) 10.4 19.0 19.1 12.9 11.1 8.2 UK ANZ FY20 FY21 FY22 FY23 FY24 40.4 37.1 45% 57% 41% 39% 29% 34.4 10.0 7.5 6.2 25.9 2.3 2.3 71% 4.9 3.4 Revenue 18.6 5.6 3.1 24.7
Slide 14: Our revenue model and breakdown
Our revenue model and breakdown… Licence fees + Maintenance & Support (M&S) recurring revenue will underpin future sustainable and increasingly profitable growth Products ~95%1 Technical Services ~5%1 Core Offering Key Product / Data analytics, Integration, Services interoperability & technical desi
Slide 15: Balance Sheet
Balance Sheet Balance sheet ($000) FY23 FY24 Cash & cash equivalents 1 14,641 11,798 1• $11.8m cash and no debt as of 30 June 2024 Trade & other receivables 2 4,735 5,214 Other assets 1,602 1,527 2• Trade receivables up on prior year; provide improved foundation Current assets 20,978 18,539 heading
Slide 16: Cash Flow
Cash Flow Cash flow ($000) FY23 FY24 Receipts from customers 46,901 43,881 • Generated positive operating cash flow in H2 of $4.3m compared to Payments to suppliers & employees (46,728) (51,004) $11.4m outflow in H1 Interest received 111 83 Finance costs (115) (89) – H2 receipts $28.8m marginally up
Slide 17: FY24 Operations
FY24 Operations
Slide 18: EPR Validation: North Cumbria
EPR Validation: North Cumbria Selected as Preferred Supplier by North Cumbria Integrated Care NHS Foundation Trust (NCIC) for new EPR platform solution Preferred Supplier - Overview Anticipated Contract Terms • Selected following a competitive tender process 10 years Contract duration • Deploy Miya
Slide 19: Our sales strategy: Modular sales driving TCV uplift
Our sales strategy: Modular sales driving TCV uplift Miya Precision’s modular design supports a ‘land & expand’ strategy to support automation and digitalization in healthcare *For illustrative purposes only Ability over time to replicate full EPR contract value ($20m - $40m) via modular add-ons $30
Slide 20: Notable Contract Wins & Renewals
Notable Contract Wins & Renewals New contracts reinforce modular strategy, catering to needs of customers as they enhance their digital maturity Hume Rural Health Alliance (AUS) South Tees NHS Trust (UK): • TCV of $4.0m over 5 years • Signed $23.3M contract extension for an additional 8 years (to 20
Slide 21: Successful Deployments in FY24
Successful Deployments in FY24 Product Implementation and technical services have always been a strength of the Alcidion business Herefordshire and Worcestershire NHS (UK) Hampshire Hospitals NHS (UK) • First deployment of Miya Precision for Flow • 1st site using Miya Emergency (ED) module and Bed M
Slide 22: Alfred Health – Independent Study on Miya Precision Benefits
Alfred Health – Independent Study on Miya Precision Benefits In 2023, Alfred Health introduced electronic patient journey boards (EPJBs) to 38 inpatient wards at The Alfred, Caufield and Sandringham hospitals. As part of the deployment, the Digital Health CRC & Monash University were engaged to cond
Slide 23: Outlook
Outlook
Slide 24: Outlook
Outlook Increased procurement activity to continue into H1’25, with re-aligned cost base positioning business well for profitability • As of August 2024, $28.0M of contracted and renewal revenue expected to be recognised in FY25 (which the Company would expect to further build upon as the year progr
Slide 25: New Board Appointment
New Board Appointment • Will Smart appointed as Non-Executive Director from 1 October 2024 • Will is a global digital health leader at both an operational and non-executive level having recently stepped down as the Global Director of External Relations, Dedalus Group, a global digital health company
Slide 26: Investment Highlights
Investment Highlights • Large Addressable Market Strong Financial Profile Marquee Customers • 146 Acute UK NHS Trusts; ALC with foothold • ~71% recurring product revenue, supported • Selected as preferred supplier for new EPR in only ~27% by multi-year contracts to North Cumbria; TCV $30-40m over 10
Slide 27: Disclaimer
Disclaimer The information contained in this document (“Document”) has been prepared by Alcidion Group Limited ACN 143 142 410 (referred to as “Alcidion” or “Company”). This Document is current as at the date of this Document and should be read in conjunction with other Alcidion periodic and continu
Slide 28: Slide 28